Factors affecting regular monitoring in patients with chronic myeloid leukemia who received tyrosine kinase inhibitor
10.3760/cma.j.issn.1009-9921.2019.01.010
- VernacularTitle:接受酪氨酸激酶抑制剂治疗慢性粒细胞 白血病患者定期监测的影响因素分析
- Author:
Yingling ZU
1
;
Yanli ZHANG
;
Jian ZHOU
;
Fengkuan YU
;
Huifang ZHAO
;
Ruirui GUI
;
Zhen LI
;
Yujie HOU
;
Yongping SONG
Author Information
1. 郑州大学附属肿瘤医院 河南省肿瘤医院血液科 河南省血液病研究所 450008
- Keywords:
Leukemia,myelogenous,chronic;
Tyrosine kinase inhibitors;
Regular monitoring;
Compliance
- From:
Journal of Leukemia & Lymphoma
2019;28(1):39-42
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe regular monitoring in patients with chronic myeloid leukemia (CML) who received tyrosine kinase inhibitor (TKI), and to analyze its influencing factors. Methods A total of 857 patients with CML in Henan Tumor Hospital from October 2012 to October 2016 were collected. Patients were told to receive regular monitoring after receiving TKI treatment, including blood routine, bone marrow, BCR-ABL fusion gene and chromosomes. All patients were divided into good and poor compliance groups according to regular monitoring. Chi-square test was used to compare ABL kinase domain mutations rate and mortality between two groups. TKI species, level of education, duration from diagnosis to treatment, teaching times, sites of follow-up, convenience of transportation, annual income and gender were recorded respectively, and the factors affecting regular monitoring were analyzed by using single and multiple factor analysis. Results There were 390 and 467 patients in good and poor compliance groups respectively. Treatment failure rate was 19.49％ (76/390) and 25.91％ (121/467) in good and poor compliance groups respectively, the mutation rate was 28.95％ (22/76) and 7.44％ (9/121) respectively. The difference of ABL kinase domain mutation in patients with treatment failure of both groups was statistically significant (χ 2 =16.287, P < 0.01). The mortality was 0.77％ (3/390) in good compliance group, and 2.78％ (13/467) in poor compliance group, and the difference was statistically significant (χ 2 = 4.543, P = 0.033). The single factors analysis showed that TKI species, level of education, duration from diagnosis to treatment, teaching times, sites of follow-up, convenience of traffic and annual income were related with regular monitoring (all P < 0.05). Multiple-factor analysis showed that inconvenient transportation (β = 1.56, 95％ CI 1.74-3.74, P = 0.014), low education level (β = 1.67, 95％ CI 0.81-3.12, P = 0.041) and low income (β = 2.87, 95％ CI 1.31-4.51, 95％CI 1.74-3.74, P = 0.011) were independent factors for poor compliance in regular monitoring. In the result detection, 56 fusion genes fluctuated. Conclusions CML patients who received regular monitoring have a low treatment failure rate and mortality. Inconvenient transportation, low education level and low outcome are independent risk factors for regular monitoring. The single monitoring result can not prompt treatment effect, and thus it needs to review and monitor for many times.
